Stojcev Zoran, Bobowicz Maciej, Jarząb Michał, Pawłowska-Stojcev Tomasz, Banasiewicz Tomasz
Pol Przegl Chir. 2013 Aug;85(8):433-7. doi: 10.2478/pjs.2013.85.8.433.
Over the last decade, gastric cancer treatment has changed from extensive multiorgan resections towards less invasive approaches with limited resections and a more selective lymphadenectomy. Despite all available trials, the conclusions on the extent of necessary resections still remain debatable. The aim of the study was to assess the short term outcomes (morbidity and mortality) of a total gastrectomy depending on the simultaneous splenectomy status.
We performed a retrospective analysis of the records of all patients treated with a curative intent using a total gastrectomy for gastric cancer between 1997 and 2003. 49 patients fulfilled the inclusion criteria. Patients were divided into two groups: S(+) gastrectomy with splenectomy group (29 patients) and S(-) total gastrectomy with spleen preservation (20 patients).
Survival analysis at one year showed that there was no difference in survival between the two groups (p=0.84). There were six recurrences, one in the group S(+) and five in group S(-) (p>0.05). Dissemination was observed in three patients in group S(-) (p>0.05). Other complications including infectious complications, exenteration, subileus, cardiovascular insufficiency, multiorgan failure were more frequent in the S(+) group (31% v 15%) although the difference was not significant (p=0.17).
Splenectomy during gastrectomy for cancer has no statistically significant impact on short-term morbidity and mortality. Even though it does not show benefit in terms of 5-year overall survival rates it might be performed when needed in more advanced cases in properly selected patients (e.g. upper gastric T3/4 gastric cancer).
在过去十年中,胃癌治疗已从广泛的多器官切除转向侵入性较小的方法,包括有限切除和更具选择性的淋巴结清扫术。尽管有所有可用的试验,但关于必要切除范围的结论仍存在争议。本研究的目的是评估全胃切除术的短期结局(发病率和死亡率),具体取决于同时进行脾切除术的情况。
我们对1997年至2003年间所有接受根治性全胃切除术治疗胃癌的患者记录进行了回顾性分析。49名患者符合纳入标准。患者分为两组:行脾切除术的S(+)胃切除术组(29例患者)和保留脾脏的S(-)全胃切除术组(20例患者)。
一年的生存分析表明,两组之间的生存率没有差异(p = 0.84)。有6例复发,S(+)组1例,S(-)组5例(p>0.05)。在S(-)组中有3例观察到播散(p>0.05)。其他并发症包括感染性并发症、脏器切除、肠梗阻、心血管功能不全、多器官功能衰竭在S(+)组中更常见(31%对15%),尽管差异不显著(p = 0.17)。
胃癌胃切除术中的脾切除术对短期发病率和死亡率没有统计学上的显著影响。尽管在5年总生存率方面未显示出益处,但在适当选择的患者中,对于更晚期的病例(例如胃上部T3/4期胃癌),可能在需要时进行。